RxDoctor Payments Data

Shideh Amirifeli, MD

Internal Medicine · Worcester, MANPI 1083763890

Payments from drug & device makers

$1,135in general payments, 2019–2025

Across 16 payments — averaging $70.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$788
  • AstraZeneca$213
  • Neurocrine Biosciences, Inc.$135

What the payments were for

  • Food & beverage$1,135100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,135 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$246,407
Medicare patients
333
Services billed
1,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban808$169,933
BiktarvyBictegrav/Emtricit/Tenofov Ala54$52,437
TivicayDolutegravir Sodium46$29,876
DescovyEmtricitabine/Tenofov Alafenam46$29,139
Divalproex Sodium636$18,849
Atorvastatin Calcium1,949$16,592
JardianceEmpagliflozin87$14,366
TrulicityDulaglutide17$11,729
Trazodone Hcl1,662$11,109
Sevelamer Hcl30$10,376
LinzessLinaclotide18$10,361
TradjentaLinagliptin67$9,224
Incruse ElliptaUmeclidinium Bromide24$8,960
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,505
LokelmaSodium Zirconium Cyclosilicate24$8,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$213$15,49274 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →